Skip to content
10-K

Annual Report

Monte Rosa Therapeutics, Inc. GLUE

0001193125-26-109360

← back to feed
Filed
Mar 17, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 2, 2026 80.02M sh
Shares Diluted FY 2025 · Dec 31, 2025 83.07M sh
Shares Diluted FY 2025 · Dec 31, 2024 73.91M sh
Dividends Paid FY 2025 · Dec 31, 2025 $0
Capex FY 2025 · Dec 31, 2025 $4.7M
Capex FY 2025 · Dec 31, 2024 $3.99M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$22.8M
Operating Cash Flow FY 2025 · Dec 31, 2024 $42M
Cash And Equivalents FY 2025 · Dec 31, 2025 $129.88M
Cash And Equivalents FY 2025 · Dec 31, 2024 $224.25M
Stockholders Equity FY 2025 · Dec 31, 2025 $233.06M
Stockholders Equity FY 2025 · Dec 31, 2024 $222.94M
Stockholders Equity FY 2025 · Dec 31, 2023 $179.25M
Current Liabilities FY 2025 · Dec 31, 2025 $64.21M
Current Liabilities FY 2025 · Dec 31, 2024 $156.95M
Total Liabilities FY 2025 · Dec 31, 2025 $215.6M
Total Liabilities FY 2025 · Dec 31, 2024 $215.8M
Current Assets FY 2025 · Dec 31, 2025 $393.19M
Current Assets FY 2025 · Dec 31, 2024 $377.44M
Total Assets FY 2025 · Dec 31, 2025 $448.66M
Total Assets FY 2025 · Dec 31, 2024 $438.73M
Sga Expense FY 2025 · Dec 31, 2025 $36.38M
Sga Expense FY 2025 · Dec 31, 2024 $35.17M
Rd Expense FY 2025 · Dec 31, 2025 $141.5M
Rd Expense FY 2025 · Dec 31, 2024 $121.56M
Net Income FY 2025 · Dec 31, 2025 −$38.63M
Net Income FY 2025 · Dec 31, 2024 −$72.7M
Operating Income FY 2025 · Dec 31, 2025 −$54.21M
Operating Income FY 2025 · Dec 31, 2024 −$81.11M
Revenue FY 2025 · Dec 31, 2025 $123.67M
Revenue FY 2025 · Dec 31, 2024 $75.62M